Assessing Virologic Success and Metabolic Changes in Patients Switching From a TDF to TAF Containing Antiretroviral Therapy Regimen

Completed

Conditions studied: HIV-1-infection, Metabolic Syndrome, Cardiovascular Diseases, Weight Gain, Renal Function Abnormal, Hyperglycemia

In brief

Switching patients with HIV infection from tenofovir disoproxil fumarate (TDF) to a tenofovir alafenamide (TAF) based drug regimen can provide many safety benefits including preserving bone mineral density and kidney function. This study will examine metabolic changes that patients may encounter due to the switch in medication regimens and the maintenance of viral suppression.

Key facts

Study ID

NCT03646370

Run by

Thomas Jefferson University

People needed

110

Starts

2018-07-25

Expected to finish

2019-07-24

Last updated by the study team

2019-09-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with HIV who are virally suppressed receiving a tenofovir disoproxil fumarate-based antiretroviral therapy regimen that switched to tenofovir alafenamide without switching any other components of their medications.

You may not qualify if…

• Patients are excluded if their switch was prior to 2015

Where it is running

• Thomas Jeffeson University — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.